UBS Group
HQL

UBS Group’s abrdn Life Sciences Investors HQL Stock Holding History

UBS Group’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
19,758
+1,145
+6% +$19.1K ﹤0.01% 6367
2025
Q4 		$312K Sell
18,613
-18,173
-49% -$305K ﹤0.01% 6339
2025
Q3 		$571K Sell
36,786
-5,298
-13% -$72.5K ﹤0.01% 5993
2025
Q2 		$539K Buy
42,084
+4,675
+12% +$57.6K ﹤0.01% 5942
2025
Q1 		$475K Sell
37,409
-30,755
-45% -$416K ﹤0.01% 5892
2024
Q4 		$894K Buy
68,164
+17,878
+36% +$258K ﹤0.01% 5389
2024
Q3 		$758K Sell
50,286
-6,770
-12% -$102K ﹤0.01% 4893
2024
Q2 		$808K Buy
57,056
+14,749
+35% +$199K ﹤0.01% 4610
2024
Q1 		$577K Buy
42,307
+5,363
+15% +$74.2K ﹤0.01% 5089
2023
Q4 		$497K Sell
36,944
-6,961
-16% -$85.6K ﹤0.01% 5114
2023
Q3 		$547K Sell
43,905
-4,268
-9% -$56.1K ﹤0.01% 4587
2023
Q2 		$652K Buy
48,173
+2,117
+5% +$29.2K ﹤0.01% 4596
2023
Q1 		$642K Sell
46,056
-6,211
-12% -$88.8K ﹤0.01% 4498
2022
Q4 		$743K Sell
52,267
-11,696
-18% -$169K ﹤0.01% 4338
2022
Q3 		$874K Sell
63,963
-18,300
-22% -$273K ﹤0.01% 3861
2022
Q2 		$1.17M Sell
82,263
-27,029
-25% -$408K ﹤0.01% 3606
2022
Q1 		$1.81M Sell
109,292
-12,524
-10% -$216K ﹤0.01% 3527
2021
Q4 		$2.34M Buy
121,816
+4,093
+3% +$82.4K ﹤0.01% 3587
2021
Q3 		$2.45M Buy
117,723
+2,973
+3% +$63.6K ﹤0.01% 3402
2021
Q2 		$2.46M Sell
114,750
-6,818
-6% -$138K ﹤0.01% 3389
2021
Q1 		$2.4M Buy
121,568
+16,784
+16% +$346K ﹤0.01% 3381
2020
Q4 		$2.07M Buy
104,784
+5,414
+5% +$100K ﹤0.01% 3381
2020
Q3 		$1.75M Buy
99,370
+6,516
+7% +$117K ﹤0.01% 3171
2020
Q2 		$1.67M Buy
92,854
+60,333
+186% +$1.03M ﹤0.01% 3045
2020
Q1 		$487K Sell
32,521
-1,561
-5% -$25.6K ﹤0.01% 3979
2019
Q4 		$594K Buy
34,082
+12,457
+58% +$204K ﹤0.01% 4673
2019
Q3 		$326K Sell
21,625
-663
-3% -$10.6K ﹤0.01% 4886
2019
Q2 		$375K Sell
22,288
-1,715
-7% -$28.2K ﹤0.01% 4499
2019
Q1 		$411K Buy
24,003
+3,075
+15% +$53.1K ﹤0.01% 4174
2018
Q4 		$316K Sell
20,928
-1,917
-8% -$33.8K ﹤0.01% 4596
2018
Q3 		$466K Sell
22,845
-18,220
-44% -$362K ﹤0.01% 4462
2018
Q2 		$772K Sell
41,065
-5,580
-12% -$105K ﹤0.01% 3980
2018
Q1 		$896K Buy
46,645
+2,580
+6% +$51.7K ﹤0.01% 3798
2017
Q4 		$865K Sell
44,065
-23,729
-35% -$475K ﹤0.01% 3896
2017
Q3 		$1.46M Buy
67,794
+13,022
+24% +$277K ﹤0.01% 3388
2017
Q2 		$1.14M Sell
54,772
-8,072
-13% -$163K ﹤0.01% 3499
2017
Q1 		$1.22M Sell
62,844
-7,253
-10% -$134K ﹤0.01% 3377
2016
Q4 		$1.19M Buy
70,097
+10,825
+18% +$190K ﹤0.01% 3402
2016
Q3 		$1.11M Sell
59,272
-15,212
-20% -$287K ﹤0.01% 3337
2016
Q2 		$1.28M Buy
74,484
+11,252
+18% +$208K ﹤0.01% 3159
2016
Q1 		$1.13M Sell
63,232
-35,859
-36% -$651K ﹤0.01% 3148
2015
Q4 		$2.34M Buy
99,091
+21,273
+27% +$528K ﹤0.01% 2652
2015
Q3 		$1.75M Sell
77,818
-20,893
-21% -$585K ﹤0.01% 2864
2015
Q2 		$2.79M Sell
98,711
-8,731
-8% -$242K ﹤0.01% 2656
2015
Q1 		$2.96M Buy
107,442
+27,567
+35% +$752K ﹤0.01% 2560
2014
Q4 		$1.99M Buy
+79,875
New +$1.92M ﹤0.01% 2911

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

UBS Group's HQL Position: Q1 2026 in Review

UBS Group increased its abrdn Life Sciences Investors (HQL) stake by 6.2% in Q1 2026, buying an estimated $19.1K and bringing the position to 19,758 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #6367.

UBS Group first reported a position in HQL in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.96M in Q1 2015. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • UBS Group held 19,758 shares of abrdn Life Sciences Investors worth $321K as of Q1 2026.
  • UBS Group bought 1,145 abrdn Life Sciences Investors shares in Q1 2026, an estimated $19.1K.
  • abrdn Life Sciences Investors made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6367 holding.
  • UBS Group first reported a position in abrdn Life Sciences Investors in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's abrdn Life Sciences Investors position peaked at $2.96M in Q1 2015.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.